In line with these findings, in vivo studies in transgenic Huntington’s disease rats have demonstrated elevated TGF-β signaling within the SGZ, reducing proliferation of NSCs and thereby decreasing DCX-positive cells and neurogenesis (69). The gene discussed is TGFB1; the disease is juvenile Huntington disease.